Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
    • Medical Information
Chat Click to chat
Question Submit a question

Information Request

Lilly Rep Request

Expand contact lilly
Lilly

You are now leaving the Lilly Medical Web site

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.

  1. Medical Information Right
  2. Cyramza® (ramucirumab) Right
  3. How do I manage extravasation with Cyramza® (ramucirumab)?
Search ramucirumab information
Search Medical Information


Tips for searching:

• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences

Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.

Cyramza ® (ramucirumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Back to search result(s)

How do I manage extravasation with Cyramza® (ramucirumab)?

If extravasation occurs or is suspected, follow your local procedures for managing non-vesicant extravasation or use local cold compresses.

UK_cFAQ_RAM130_EXTRAVASATION
UK_cFAQ_RAM130_EXTRAVASATION
en-GB

Recommendations from the European Society for Medical Oncology - The European Oncology Nursing Society (ESMO-EONS)

The European Society for Medical Oncology-The European Oncology Nursing Society (ESMO-EONS) Clinical Practice Guidelines recommend using local dry cold compresses for non-vesicants such as ramucirumab if extravasation does occur.1

Cyramza is not a vesicant

Ramucirumab is a non-vesicant as it is an antibody in a neutral formulation. It is not likely to cause extravasation. 

No dedicated extravasation studies have been conducted in animals. However, local tolerance was investigated in 2 repeat-dose toxicity evaluations in cynomolgus monkeys by clinical observations and as part of the histopathological evaluations.

Intravenous administration of ramucirumab was well tolerated at all dose levels.

Mild, local injection-site reactions were observed and consisted of mononuclear and/or polymorphonuclear cells in the perivascular areas.2

References

1Perez Fidalgo JA, Garcia Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012;Suppl 7:vii167-73. http://annonc.oxfordjournals.org/content/23/suppl_7/vii167

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 25 April 2022

Was this answer helpful?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms and conditions
  • Privacy Policy & Cookies
  • Accessibility Information
  • Cookie settings

    MI-LM-UK-1006 Oct-2023 | ® Registered Trademark of Eli Lilly and Company | © Eli Lilly and Company 2023.

    This site is published by Eli Lilly and Company Ltd and is intended for Healthcare Professionals in the United Kingdom

    Lilly